-
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-18 Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W. Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, Nathalia Gandur, Elaine T. Lam, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J. Crabb, Robert Kemp, Javier
-
Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-17 Sangjoon Choi, Mofazzal Hossain, Hyun Lee, Jina Baek, Hye Seon Park, Chae-Lyul Lim, DoYeon Han, Taehyun Park, Jong Hyeok Kim, Gyungyub Gong, Mi-Na Kweon, Hee Jin Lee
-
Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-17 Sha Ma, Ying Wang, Kunming Qi, Wenyi Lu, Yuekun Qi, Jiang Cao, Mingshan Niu, Depeng Li, Wei Sang, Zhiling Yan, Feng Zhu, Hai Cheng, Zhenyu Li, Mingfeng Zhao, Kailin Xu
-
Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-17 Sophia Stock, Luisa Fertig, Adrian Gottschlich, Janina Dörr, Florian Märkl, Lina Majed, Vivien D. Menkhoff, Ruth Grünmeier, Kai Rejeski, David M. Cordas dos Santos, Sebastian Theurich, Michael von Bergwelt-Baildon, Stefan Endres, Marion Subklewe, Sebastian Kobold
-
TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-17 Junseok Lee, Keon-Il Im, Sojin Gil, Hyemin Na, Gi-June Min, Nayoun Kim, Seok-Goo Cho
-
Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-17 Lanqun Qin, Guiying Zhang, Yirong Wu, Yueling Yang, Zhengyun Zou
-
T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-15 Ling Yi, Ziwei Xu, Tianyu Ma, Chong Wang, Panjian Wei, Bo Xiao, Hongtao Zhang, Nanying Che, Zhidong Liu, Yi Han
-
CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-15 Jessica Wedig, Shrina Jasani, Debasmita Mukherjee, Hannah Lathrop, Priya Matreja, Timothy Pfau, Liliana D’Alesio, Abigail Guenther, Lexie Fenn, Morgan Kaiser, Molly A. Torok, Jake McGue, Gina M. Sizemore, Anne M. Noonan, Mary E. Dillhoff, Bradley W. Blaser, Timothy L. Frankel, Stacey Culp, Phil A. Hart, Zobeida Cruz-Monserrate, Thomas A. Mace
-
Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-15 Nithidol Sakunrangsit, Nattarika Khuisangeam, Thananya Inthanachai, Varalee Yodsurang, Pasrawin Taechawattananant, Koramit Suppipat, Supannikar Tawinwung
-
Integrating bulk and single-cell sequencing data to construct a Scissor+ dendritic cells prognostic model for predicting prognosis and immune responses in ESCC Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-15 Maosheng Cheng, Jianqi Xiong, Qianwen Liu, Caihua Zhang, Kang Li, Xinyuan Wang, Shuang Chen
-
Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-12 Ziyang Xu, Wenbin Jiang, Li Liu, Youqi Qiu, Jiahao Wang, Siyuan Dai, Jianming Guo, Jiejie Xu
-
The prognostic and potentially immunomodulatory role of cartilage oligomeric matrix protein in patients with gastric and esophageal adenocarcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-02
Abstract Background Cartilage oligomeric matrix protein (COMP) is a novel regulator of the tumor microenvironment. Studies in colon cancer and pancreatobiliary adenocarcinoma have revealed COMP expression to be associated with decreased infiltration of immune cells in the tumor microenvironment. Herein, the expression of COMP was investigated in gastric and esophageal adenocarcinoma with particular
-
Activation of STING by the novel liposomal TLC388 enhances the therapeutic response to anti-PD-1 antibodies in combination with radiotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-02 Jhen-Yu Chen, Po-Yu Lin, Wei-Ze Hong, Pei-Chen Yang, Shu-Fen Chiang, Hsin-Yu Chang, Tao-Wei Ke, Ji-An Liang, William Tzu-Liang Chen, K. S. Clifford Chao, Kevin Chih-Yang Huang
Current immune checkpoint inhibiters (ICIs) have contrasting clinical results in poorly immunogenic cancers such as microsatellite-stable colorectal cancer (MSS-CRC). Therefore, understanding and developing the combinational therapeutics for ICI-unresponsive cancers is critical. Here, we demonstrated that the novel topoisomerase I inhibitor TLC388 can reshape the tumor immune landscape, corroborating
-
Bifidobacterium modulation of tumor immunotherapy and its mechanism Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-04-02 Bo Pei, Shixuan Peng, Chuying Huang, Fuxiang Zhou
The advent of tumor immunotherapy in patients has revolutionized the treatment of tumors and significantly improved survival rates for a wide range of tumors. However, the full therapeutic potential of immune checkpoint inhibitors (ICIs) has yet to be realized, as not all patients have a lasting survival benefit from them, and a significant proportion of patients show primary or acquired resistance
-
Efficacy of immune checkpoint inhibitors differs in various status of carcinoma: a study based on 29 cohorts with 3255 participants Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Chunlan Wu, Yujun Ke, Luying Wan, Xianhe Xie
Background Pre-clinical data have revealed that viral infection, such as Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Papilloma virus (HPV), may lead to the development of “hot” or “immune-sensitive” tumors, which may impact the efficacy of immune checkpoint inhibitor (ICIs). Therefore, This study aimed to investigate the impact of viral status on the efficacy of ICIs. Methods Electronic
-
Ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients with advanced solid tumours Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Manish R. Patel, Melissa Johnson, Ira Winer, Hendrik-Tobias Arkenau, Natalie Cook, Vanessa Samouëlian, Raid Aljumaily, Shigehisa Kitano, Christine Duffy, Miaomiao Ge, Mabrouk Elgadi, Lillian L. Siu
Background Ezabenlimab (BI 754091) is a humanised monoclonal antibody targeting programmed cell death protein-1. We report results from open-label, dose-escalation/expansion, Phase I trials that evaluated the safety, maximum tolerated dose (MTD), pharmacokinetics and antitumour activity of ezabenlimab at the recommended Phase II dose in patients with selected advanced solid tumours. Study design Study
-
Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Jennifer W. Cao, Jessica Lake, Renata Impastato, Lyndah Chow, Luisanny Perez, Laura Chubb, Jade Kurihara, Michael R. Verneris, Steven Dow
The use of large animal spontaneous models of solid cancers, such as dogs with osteosarcoma (OS), can help develop new cancer immunotherapy approaches, including chimeric antigen receptor (CAR) T cells. The goal of the present study was to generate canine CAR T cells targeting the B7-H3 (CD276) co-stimulatory molecule overexpressed by several solid cancers, including OS in both humans and dogs, and
-
SFRP1 decreases WNT-Mediated M2 macrophage marker expression in breast tissue Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Kelly J. Gregory, Holly Mason, Jesse Casaubon, Sallie S. Schneider
The Wnt family of secreted proteins are involved in mammary gland development and tumorigenesis. It has recently been shown that Wnt ligands promote M2 macrophage polarization and so we sought to determine the effects of a Wnt signaling antagonist, Secreted Frizzled Related Protein 1 (SFRP1), on M2 marker expression. We measured a murine M2 marker (Arg1) in mice with a targeted deletion of Sfrp1 during
-
Prenatal inflammation exposure accelerates lung cancer tumorigenesis in offspring mouse: possible links to IRE1α/XBP1-mediated M2-like polarization of TAMs and PD-L1 up-expression Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Jingbo Ma, Jian Tan, Weiqiang Zhang, Miaochun Bai, Keqiang Liu
Background Prenatal inflammation exposure (PIE) can increase the disease susceptibility in offspring such as lung cancer. Our purpose was to investigate the mechanisms of PIE on lung cancer. Methods Prenatal BALB/c mice were exposed to lipopolysaccharide (LPS), and then, their offspring were intraperitoneally instilled with urethane to establish the two-stage lung cancer carcinogenesis model. At the
-
DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Zhe Ma, Zhenxing Zhou, Wenwen Duan, Gaofeng Yao, Shimei Sheng, Sidou Zong, Xin Zhang, Changkui Li, Yuanyuan Liu, Fengting Ou, Maha Raja Dahar, Yanshan Huang, Lushan Yu
Background Claudin 18.2 (CLDN18.2) is a highly anticipated target for solid tumor therapy, especially in advanced gastric carcinoma and pancreatic carcinoma. The T cell engager targeting CLDN18.2 represents a compelling strategy for enhancing anti-cancer efficacy. Methods Based on the in-house screened anti-CLDN18.2 VHH, we have developed a novel tri-specific T cell engager targeting CLDN18.2 for gastric
-
Lipid droplets-related Perilipin-3: potential immune checkpoint and oncogene in oral squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Yijia He, Lingyun Liu, Yuexin Dong, Xiaoxin Zhang, Yuxian Song, Yue Jing, Yanhong Ni, Yi Wang, Zhiyong Wang, Liang Ding
Background Lipid droplets (LDs) as major lipid storage organelles are recently reported to be innate immune hubs. Perilipin-3 (PLIN3) is indispensable for the formation and accumulation of LDs. Since cancer patients show dysregulated lipid metabolism, we aimed to elaborate the role of LDs-related PLIN3 in oral squamous cell carcinoma (OSCC). Methods PLIN3 expression patterns (n = 87), its immune-related
-
IL7 in combination with radiotherapy stimulates a memory T-cell response to improve outcomes in HNSCC models Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Justin Yu, Jacob Gadwa, Richard B. Ross, Michael Knitz, Laurel B. Darragh, Khalid N. M. Abdelazeem, Jessica Beynor, Brooke Neupert, Alexander Nguyen, Diemmy Nguyen, Nicholas Olimpo, Sophia Corbo, Benjamin Van Court, Angelo D’Alessandro, Anthony Saviola, Sana D. Karam
Clinically approved head and neck squamous cell carcinoma (HNSCC) immunotherapies manipulate the immune checkpoint blockade (ICB) axis but have had limited success outside of recurrent/metastatic disease. Interleukin-7 (IL7) has been shown to be essential for effector T-cell survival, activation, and proliferation. Here, we show that IL7 in combination with radiotherapy (RT) is effective in activating
-
IL-2 promotes expansion and intratumoral accumulation of tumor infiltrating dendritic cells in pancreatic cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Tingting Gong, Xinyang Huang, Zhuoxin Wang, Ye Chu, Lifu Wang, Qi Wang
This study aims to investigate the diagnostic potential of IL-2 for PDAC and develop a method to improve the dendritic cell (DC) based vaccine against PDAC. The gene expression data and clinical characteristics information for 178 patients with PDAC were obtained from The Cancer Genome Atlas (TCGA). DCs were isolated from Human peripheral blood mononuclear cells (PBMCs) and were cultured in 4 different
-
Characterization of a novel anti-PVRIG antibody with Fc-competent function that exerts strong antitumor effects via NK activation in preclinical models Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Hongyu Xue, Zhimin Zhang, Li Li, Chenjuan Zhu, Keke Fei, Huijun Sha, Zhihai Wu, Xiaomin Lin, Feifei Wang, Shuaixiang Zhou, Xiya Deng, Yiming Li, Bingliang Chen, Yao Xiong, Kai Chen
Poliovirus receptor-related immunoglobulin domain-containing protein, or PVRIG, is a newly discovered immune checkpoint that has emerged as a promising target for cancer immunotherapy. It is primarily expressed on activated T and natural killer (NK) cells, and once engaged with its ligand, PVRL2, it induces inhibitory signaling in T cells, thereby promoting the functional exhaustion of tumor-infiltrating
-
23-Hydroxybetulinic acid attenuates 5-fluorouracil resistance of colorectal cancer by modulating M2 macrophage polarization via STAT6 signaling Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Zeping Fan, Yaru Cui, Lanying Chen, Peng Liu, Wenbin Duan
Macrophage polarization is closely associated with the inflammatory processes involved in the development and chemoresistance of colorectal cancer (CRC). M2 macrophages, the predominant subtype of tumor-associated macrophages (TAMs) in a wide variety of malignancies, have been demonstrated to promote the resistance of CRC to multiple chemotherapeutic drugs, such as 5-fluorouracil (5-FU). In our study
-
PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAM Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Ting Zhou, Husun Qian, Dian Zhang, Wenli Fang, MengLi Yao, He Shi, Tingmei Chen, Chengsen Chai, Bianqin Guo
Background Tumor microenvironment actually reduces antitumor effect against the immune attack by exclusion of CD8+T cells. Progranulin (PGRN) is a multifunctional growth factor with significant pathological effects in multiple tumors; however, its role in immunity evasion of breast cancer (BCa) is not completely understood. Methods We depleted GRN (PGRN gene) genetically in mice or specifically in
-
Let-7i enhances anti-tumour immunity and suppresses ovarian tumour growth Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30
Abstract Cancer immunotherapy has seen significant success in the last decade for cancer management by enhancing endogenous cancer immunity. However, immunotherapies developed thus far have seen limited success in the majority of high-grade serous carcinoma (HGSC) ovarian cancer patients. This is largely due to the highly immunosuppressive tumour microenvironment of HGSC and late-stage identification
-
circFTO from M2 macrophage-derived small extracellular vesicles (sEV) enhances NSCLC malignancy by regulation miR-148a-3pPDK4 axis Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Qingtao Liu, Pei Xu, Mingming Jin, Lei Wang, Fengqing Hu, Qi Yang, Rui Bi, Haibo Xiao, Lianyong Jiang, Fangbao Ding
Background Accumulation studies found that tumor-associated macrophages (TAMs) are a predominant cell in tumor microenvironment (TME), which function essentially during tumor progression. By releasing bioactive molecules, including circRNA, small extracellular vesicles (sEV) modulate immune cell functions in the TME, thereby affecting non-small cell lung cancer (NSCLC) progression. Nevertheless, biology
-
The radiomics nomogram predicts the prognosis of pancreatic cancer patients with hepatic metastasis after chemoimmunotherapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30
Abstract Objective To construct a prognostic model based on MR features and clinical data to evaluate the progression free survival (PFS), overall survival (OS) and objective response rate (ORR) of pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy. Methods 105 pancreatic cancer patients with hepatic metastases who received chemoimmunotherapy were assigned to the training
-
TGF-β1 and TGF-βR1 variants are associated with clinical outcomes in smoking-related head and neck cancer patients treated with chemoradiation through modulating microRNA-mediated regulation Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-30 Zihao Niu, Peng Sun, Mark E. Zafereo, Hongliang Liu, Peng Wei, Jia Wu, Neil D. Gross, Sanjay Shete, Qingyi Wei, Guibin Zheng, Andy G. Sikora, George A. Calin, Guojun Li
TGF-β1 and TGF-βR1 play important roles in immune and inflammatory responses. Genetic variants of TGF-β1 rs1800470 and TGF-βR1 rs334348 have emerged as potentially prognostic biomarkers for HPV-related head and neck cancer, while their prognostic effect on survival of smoking-related head and neck cancer remains unknown. This study included 1403 patients with smoking-related head and neck cancer, and
-
Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-27 Kaiqi Zhang, Yuan Xu, Xusheng Chang, Caili Xu, Wenjing Xue, Dan Ding, Mingming Nie, Hui Cai, Jun Xu, Lu Zhan, Jiangbo Han, Tiancai Cai, Dianwen Ju, Li Feng, Xuyao Zhang, Kai Yin
-
Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-07
Abstract Background Pembrolizumab has been indicated in the treatment of solid tumors with high frequency microsatellite instability (MSI-H) or high tumor mutational burden (TMB-H); however, real-world data on the effectiveness of pembrolizumab with or without chemotherapy in this molecular subset remain limited. Our retrospective study evaluated the clinical efficacy and safety of pembrolizumab in
-
Clinical immunotherapy in pancreatic cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Xiaorong Ye, Yue Yu, Xiaohu Zheng, Hongdi Ma
-
Integrating molecular subtype and CD8+ T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Bingyu Li, Kaifeng Jin, Zhaopei Liu, Xiaohe Su, Ziyue Xu, Ge Liu, Jingtong Xu, Hailong Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Weijuan Zhang
-
Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Jiawei Yue, Hui Guo, Peng Xu, Jinhong Ma, Weifeng Shi, Yumin Wu
-
Riboflavin-LSD1 axis participates in the in vivo tumor-associated macrophage morphology in human colorectal liver metastases Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Cristiana Soldani, Giulia De Simone, Michela Anna Polidoro, Aurelia Morabito, Barbara Franceschini, Federico Simone Colombo, Achille Anselmo, Flavio Milana, Ana Lleo, Guido Torzilli, Roberta Pastorelli, Matteo Donadon, Laura Brunelli
-
Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Xinru Fan, Zijun Yan, Yunkai Lin, Qing Wang, Li Jiang, Xiaomeng Yao, Liwei Dong, Lei Chen, Tuan Zhao, Jieqiong Zhao, Heping Hu, Hui Wang
-
Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Jianguo Zhang, Yangyi Li, Weijing Dai, Fang Tang, Lanqing Wang, Zhiying Wang, Siqi Li, Qian Ji, Junhong Zhang, Zhengkai Liao, Jing Yu, Yu Xu, Jun Gong, Jing Hu, Jie Li, Xiuli Guo, Fajian He, Linzhi Han, Yan Gong, Wen Ouyang, Zhihao Wang, Conghua Xie
-
A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Gerald S. Falchook, James Reeves, Sunil Gandhi, David R. Spigel, Edward Arrowsmith, Daniel J. George, Janet Karlix, Gayle Pouliot, Maureen M. Hattersley, Eric T. Gangl, Gareth D. James, Jeff Thompson, Deanna L. Russell, Bhavickumar Patel, Rakesh Kumar, Emerson Lim
-
Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Tanguy Y. Seiwert, Sophie Wildsmith, Jérôme Fayette, Kevin Harrington, Maura Gillison, Myung-Ju Ahn, Shunji Takahashi, Jared Weiss, Jean-Pascal Machiels, Shrujal Baxi, Valerie Baker, Brent Evans, Nassim Morsli, Jill Walker, Katia Real, Anne L’Hernault, Amanda Psyrri
-
Ectopic CXCR2 expression cells improve the anti-tumor efficiency of CAR-T cells and remodel the immune microenvironment of pancreatic ductal adenocarcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Zhengjie Dai, Xuan Lin, Xu Wang, Xuan Zou, Yu Yan, Ruijie Wang, Yusheng Chen, Yesiboli Tasiheng, Mingjian Ma, Xu Wang, He Cheng, Xianjun Yu, Chen Liu
-
Neutrophils seeking new neighbors: radiotherapy affects the cellular framework and the spatial organization in a murine breast cancer model Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 C. M. Reichardt, M. Muñoz-Becerra, A. Rius Rigau, M. Rückert, R. Fietkau, G. Schett, U. S. Gaipl, B. Frey, L. E. Muñoz
-
Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Wenjun Liu, Xitu Luo, Zilang Zhang, Yepeng Chen, Yongliang Dai, Jianzhong Deng, Chengyu Yang, Hao Liu
-
Oct4 activates IL-17A to orchestrate M2 macrophage polarization and cervical cancer metastasis Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Zhuoqiong Bian, Xiaoling Wu, Qing Chen, Qing Gao, Xiang Xue, Yidong Wang
-
Size selection of intrahepatic lesions for cryoablation contributes to abscopal effect and long-term survival in patients with liver metastatic melanoma receiving PD-1 blockade therapy Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-03-02 Lujun Shen, Hongtong Tan, Juan Nie, Yiquan Jiang, Gulijiayina Nuerhashi, Han Qi, Fei Cao, Chunyong Wen, Shuanggang Chen, Tianqi Zhang, Wei Zheng, Peng Liu, Ying Liu, Tao Huang, Dandan Li, Xiaoshi Zhang, Weijun Fan
-
Toripalimab, a therapeutic monoclonal anti-PD-1 antibody with high binding affinity to PD-1 and enhanced potency to activate human T cells Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-24 Narendiran Rajasekaran, Xiaoguang Wang, Sruthi Ravindranathan, Daniel J Chin, Su-Yi Tseng, Scott L Klakamp, Kate Widmann, Varun N Kapoor, Vladimir Vexler, Patricia Keegan, Sheng Yao, Theresa LaVallee, Sanjay D Khare
-
Granzyme B+ B cells detected by single-cell sequencing are associated with prognosis in patients with intrahepatic cholangiocarcinoma following liver transplantation Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-22
Abstract B cells possess anti-tumor functions mediated by granzyme B, in addition to their role in antigen presentation and antibody production. However, the variations in granzyme B+ B cells between tumor and non-tumor tissues have been largely unexplored. Therefore, we integrated 25 samples from the Gene Expression Omnibus database and analyzed the tumor immune microenvironment. The findings uncovered
-
Multiplexed analysis of macrophage polarisation in pulmonary metastases of microsatellite stable colorectal cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-22 Topias Karjula, Hanna Elomaa, Sara A. Väyrynen, Teijo Kuopio, Maarit Ahtiainen, Olli Mustonen, Iiris Puro, Anne Niskakangas, Jukka-Pekka Mecklin, Jan Böhm, Erkki-Ville Wirta, Toni T. Seppälä, Eero Sihvo, Fredrik Yannopoulos, Olli Helminen, Juha P. Väyrynen
-
Targeting myeloperoxidase limits myeloid cell immunosuppression enhancing immune checkpoint therapy for pancreatic cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-17
Abstract Pancreatic ductal adenocarcinoma is a devastating disease characterized by an extreme resistance to current therapies, including immune checkpoint therapy. The limited success of immunotherapies can be attributed to a highly immunosuppressive pancreatic cancer microenvironment characterized by an extensive infiltration of immune suppressing myeloid cells. While there are several pathways through
-
Chemokine CCL21 determines immunotherapy response in hepatocellular carcinoma by affecting neutrophil polarization Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-17 Wenxin Xu, Jialei Weng, Minghao Xu, Qiang Zhou, Shaoqing Liu, Zhiqiu Hu, Ning Ren, Chenhao Zhou, Yinghao Shen
-
Induction immunotherapy plus chemotherapy followed by definitive chemoradiation therapy in locally advanced esophageal squamous cell carcinoma: a propensity-score matched study Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-16 Hui-min Lian, Jia-liang Wu, Wei-jian Liufu, Tian-tian Yu, Shao-qing Niu, Yong Bao, Fang Peng
-
Retrospective assessment of neoadjuvant camrelizumab combined with induction chemotherapy: efficacy in laryngeal preservation for advanced hypopharyngeal and laryngeal squamous cell carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-15 Jin Peng, Guangfeng Luo, Yongchao Yu, Kang Ning, Xuekui Liu
-
Immunogenic cell death in colorectal cancer: a review of mechanisms and clinical utility Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-14
Abstract Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality worldwide. Despite several clinical advances the survival of patients with advanced colorectal cancer remains limited, demanding newer approaches. The immune system plays a central role in cancer development, propagation, and treatment response. Within the bowel, the colorectal mucosa is a key barrier and site
-
Low-intensity pulsed ultrasound activated the anti-tumor immunity by irradiating the spleen of mice in 4 T-1 breast cancer Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Yi Xia, Meijie Yang, Xinfang Xiao, Wentao Tang, Juan Deng, Liu Wu, Haopeng Xu, Yilin Tang, Wenzhi Chen, Yan Wang
-
Atovaquone enhances antitumor efficacy of TCR-T therapy by augmentation of ROS-induced ferroptosis in hepatocellular carcinoma Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Anan Chen, Zhiwu Yu, Na Ma, Xinyu Lu, Yajing Zhang, Weikang Xu, Yiyue Wang, Jiayi Xie, Yuqi Qin, Guoheng Mo, Sha Wu, Jinlin Hou, Wei Zhu
-
Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Konstantinos Ntostoglou, Sofia D. P. Theodorou, Tanja Proctor, Ilias P. Nikas, Sinclair Awounvo, Athanasia Sepsa, Vassilis Georgoulias, Han Suk Ryu, Ioannis S. Pateras, Christos Kittas
-
Identification macrophage signatures in prostate cancer by single-cell sequencing and machine learning Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Zhen Kang, Yu-Xuan Zhao, Ren Shun Qian Qiu, Dong-Ning Chen, Qing-Shui Zheng, Xue-Yi Xue, Ning Xu, Yong Wei
-
INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13
Abstract Combining immunotherapies with distinct mechanisms of action has the potential to overcome treatment resistance and improve outcomes. The inducible T-cell co-stimulator (ICOS) agonist feladilimab is directed at enhancing T-cell activation and function, thereby promoting an antitumor response. INDUCE-2 (NCT03693612) was a Phase I/II, open-label, two-part study evaluating the anti-ICOS agonist
-
Investigating the immunological function of alpha-2-glycoprotein 1, zinc-binding in regulating tumor response in the breast cancer microenvironment Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Toru Hanamura, Kozue Yokoyama, Shigehisa Kitano, Hiroshi Kagamu, Makiko Yamashita, Mayako Terao, Takuho Okamura, Nobue Kumaki, Katsuto Hozumi, Takayuki Iwamoto, Chikako Honda, Sasagu Kurozumi, Jennifer K. Richer, Naoki Niikura
-
Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade Cancer Immunol. Immunother. (IF 5.8) Pub Date : 2024-02-13 Sweta Karan, Eunkyeong Jung, Christine Boone, Nicole F. Steinmetz